[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100440330":3},{"organization":4,"armGroups":7,"interventions":15,"overallOfficials":32,"centralContacts":36,"locations":42,"responsibleParty":62,"collaborators":40,"id":65,"slug":66,"hasResults":67,"nctId":68,"briefTitle":69,"officialTitle":70,"acronym":40,"eligibilityCriteria":71,"healthyVolunteers":67,"sex":72,"minAge":73,"maxAge":40,"enrollmentInfo":74,"targetDuration":40,"studyType":77,"phases":78,"briefSummary":80,"conditions":81,"keywords":83,"overallStatus":45,"whyStopped":40,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":93},{"fullName":5,"class":6},"Massachusetts General Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"NTS-WBRT (normal tissue sparing whole brain radiation therapy) + Memantine","EXPERIMENTAL","Participants will be randomly assigned to NTS-WBRT (normal tissue sparing whole brain radiation therapy) administration group and receive:\n\n* NTS-WBRT for 5 days (Monday-Friday) for either 2 or 3 weeks.\n* Memantine per standard of care, 1-2x daily for up to 24 weeks Specific participant administration schedules will be determined by study doctor",[13,14],"Radiation: NTS-WBRT (normal tissue sparing whole brain radiation therapy)","Drug: Memantine",[16,23],{"type":17,"name":18,"description":19,"armGroupLabels":20,"otherNames":21},"RADIATION","NTS-WBRT (normal tissue sparing whole brain radiation therapy)","Radiation",[9],[22],"Radiation Therapy",{"type":24,"name":25,"description":26,"armGroupLabels":27,"otherNames":28},"DRUG","Memantine","Capsule, taken orally",[9],[29,30,31],"Namenda","Namenda XR","Namenda XR Titration Pack",[33],{"name":34,"affiliation":5,"role":35},"Helen A Shih, MD, MS, MPH","PRINCIPAL_INVESTIGATOR",[37],{"name":34,"role":38,"phone":39,"phoneExt":40,"email":41},"CONTACT","(617) 724-9627",null,"hshih@mgh.harvard.edu",[43],{"facility":44,"status":45,"city":46,"state":47,"zip":48,"country":49,"countryCode":50,"cosmosGeoPoint":51,"geoPoint":56,"contacts":57},"Massachusetts General Hospital Cancer Center","RECRUITING","Boston","Massachusetts","02114","United States","US",{"type":52,"coordinates":53},"Point",[54,55],-71.05977,42.35843,{"lat":55,"lon":54},[58,61],{"name":59,"role":38,"phone":60,"phoneExt":40,"email":41},"Helen A Shih, MD,MS,MPH","617-724-9627",{"name":34,"role":35,"phone":40,"phoneExt":40,"email":40},{"type":35,"investigatorFullName":63,"investigatorTitle":64,"investigatorAffiliation":5,"oldNameTitle":40,"oldOrganization":40},"Helen A. Shih, MD","Principal Investigator","100440330","phase-2-nts-wbrt-in-brain-metastases-100440330",false,"NCT05013892","NTS-WBRT in Brain Metastases","Phase II Trial of Normal Tissue Sparing Whole Brain Radiation Therapy (NTS-WBRT) in Patients With Brain Metastases","Inclusion Criteria:\n\n* Any patient with a solid tumor diagnosis and any number of brain metastasis clinically indicated for cranial irradiation with whole brain radiation therapy\n* Age ≥ 18\n* Karnofsky Performance Status ≥ 70\n* Prior stereotactic radiosurgery (SRS) permissible per physician discretion\n* Prior craniotomy permissible per physician discretion. Protocol radiation therapy should be initiated ≥2 weeks after craniotomy.\n* Prior partial brain radiation therapy permissible if target volume \\\u003C 50% brain and per physician discretion\n* Expectant \\> 6 months survival\n* Ability to understand and the willingness to sign a written informed consent document.\n* Fluency in English, able to complete questionnaires and neurocognitive testing\n* Ability to undergo MRI with gadolinium examination\n* Ability to return for follow-up examinations throughout the course of this study for a maximum of 2 years after radiation treatment completion\n* Any prior, concomitant, or post-radiotherapy systemic therapy is permitted at discretion of treating physicians\n* Negative pregnancy test for premenopausal women\n\nExclusion Criteria:\n\n* Leptomeningeal disease (by any one or more of clinical assessment, radiographic assessment, or cerebrospinal fluid study)\n* Prior whole brain radiation therapy\n* Pre-existing or current use of memantine or other NMDA antagonists\n* Known allergy to contrast used in imaging studies and\u002For inability to have MRI imaging\n* Uncontrolled intercurrent illness that could significantly affect baseline cognitive function as determined by the enrolling clinician, such as symptomatic congestive heart failure, unstable angina pectoris, prior CVA, significant uncontrolled epilepsy or psychiatric illness\u002Fsocial situations that would limit compliance with study requirements\n* Pregnant or unwilling to use appropriate contraception to prevent pregnancy during the time of radiation therapy\n* Concurrent participation in an investigational systemic therapy protocol.","ALL","18 Years",{"count":75,"type":76},41,"ESTIMATED","INTERVENTIONAL",[79],"PHASE2","This research is being done to assess the quality of life and symptom burden in participants who receive (normal tissue sparing whole brain radiation therapy (NTS-WBRT).\n\nThis research study involves:\n\n* NTS-WBRT (normal tissue sparing whole brain radiation therapy)\n* Memantine standard of care drug",[82],"Brain Metastases",[82],"2026-04-14",{"date":86,"type":87},"2026-04-16","ACTUAL",{"date":89,"type":87},"2022-02-08",{"date":91,"type":76},"2027-12-31",{"name":5,"class":6},1]